Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jul 7, 2015; 21(25): 7860-7868
Published online Jul 7, 2015. doi: 10.3748/wjg.v21.i25.7860
Figure 2
Figure 2 Liver enzyme changes in 20 patients with non-alcoholic steatohepatitis during the 12 mo of rosuvastatin (10 mg/d) monotherapy. The reduction in serum alanine transaminase (ALT), aspartate transaminase (AST) and γ-glutamyl transpeptidase (GGT) levels became statistical significant by the 3rd month of treatment (ANOVA for the 12 mo period P < 0.001) and for alkaline phosphatase (ALP) by the 6th mo of treatment (ANOVA for the 12 mo period P = 0.01).